ICD-10-CM 2026 · Effective October 1, 2025

ICD-10 D61.82

Billable / Specific HCC v28: 46 CC

Myelophthisis

D61
Block
3
Synonyms
649
LCDs
12
Payer Policies
0
Linked CPTs

About ICD-10-CM D61.82

ICD-10-CM code D61.82 represents Myelophthisis. This is a billable/specific code in the Blood and Blood-forming Organs chapter (block D61). The 2026 edition of ICD-10-CM D61.82 became effective on October 1, 2025.

Coding Tips for D61.82

Specialist guidance from the PayerReady Medical Coding Team. Specificity warnings, HCC capture rules, sequencing notes.

HCC capture: document with MEAT each year

D61.82 is a CMS-HCC v28 risk-adjustment code (category 46). To count for the patient Risk Adjustment Factor (RAF), document the diagnosis with MEAT language each calendar year: Monitored, Evaluated, Assessed, Treated. A diagnosis on the problem list alone does not satisfy CMS RADV audit standards. Include the diagnosis in the assessment with current status and current treatment plan.

Inpatient DRG impact: CC

D61.82 is designated CC for MS-DRG grouping. On inpatient claims, this code can shift the DRG to the with-CC variant when documented as a present-on-admission secondary diagnosis. Hospital CDI programs flag CC opportunities during chart review. Failure to capture this code may leave 30 to 80 percent of the inpatient stay revenue unrealized.

Inclusion Terms / Approximate Synonyms

Clinical terms and conditions classified under D61.82. Per CMS ICD-10-CM Tabular 2026.

  • Leukoerythroblastic anemia
  • Myelophthisic anemia
  • Panmyelophthisis

Type 1 Excludes

Pure excludes, these codes can never be coded together with D61.82. The conditions are mutually exclusive (e.g., congenital vs acquired forms).

  • idiopathic myelofibrosis (D47.1)
  • myelofibrosis NOS (D75.81)
  • myelofibrosis with myeloid metaplasia (D47.4)
  • primary myelofibrosis (D47.1)
  • secondary myelofibrosis (D75.81)

Coding Notes

Code Also

  • the underlying disorder, such as:
  • malignant neoplasm of breast (C50.-)
  • tuberculosis (A15.-)

Medicare Advantage HCC Impact

CMS-HCC v28 (current)
Category 46
ESRD-HCC
Category 46
RxHCC (Part D)
Category 46

Capture this diagnosis annually for accurate risk adjustment. Missed HCC captures are the #1 revenue leak in Medicare Advantage risk programs.

Inpatient DRG Impact, CC

codes Myelophthisis. As a Complication/Comorbidity (CC), this contributes to DRG severity adjustment when documented alongside the principal diagnosis.

Medicare LCD Coverage for D61.82

Local Coverage Determinations (LCDs) from CMS MACs that list D61.82 as a covered diagnosis.

649 LCDs

Showing top 10 of 649 total . Click a CPT for full coverage scope.

CMS LCD: Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers
Article ID: 58988, Effective: 2025-04-24 00:00:00, 513 covered, 0 non-covered
CPT 81261 →
CMS LCD: Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers
Article ID: 58988, Effective: 2025-04-24 00:00:00, 513 covered, 0 non-covered
CPT 81315 →
CMS LCD: Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers
Article ID: 58988, Effective: 2025-04-24 00:00:00, 513 covered, 0 non-covered
CPT 81316 →
CMS LCD: Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers
Article ID: 58988, Effective: 2025-04-24 00:00:00, 513 covered, 0 non-covered
CPT 81479 →
CMS LCD: Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers
Article ID: 58988, Effective: 2025-04-24 00:00:00, 513 covered, 0 non-covered
CPT 81207 →
CMS LCD: Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers
Article ID: 58988, Effective: 2025-04-24 00:00:00, 513 covered, 0 non-covered
CPT 0364U →
CMS LCD: Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers
Article ID: 58988, Effective: 2025-04-24 00:00:00, 513 covered, 0 non-covered
CPT 81206 →
CMS LCD: Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers
Article ID: 58988, Effective: 2025-04-24 00:00:00, 513 covered, 0 non-covered
CPT 81263 →
CMS LCD: Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers
Article ID: 58988, Effective: 2025-04-24 00:00:00, 513 covered, 0 non-covered
CPT 81334 →
CMS LCD: Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers
Article ID: 58988, Effective: 2025-04-24 00:00:00, 513 covered, 0 non-covered
CPT 81450 →

Commercial Payer Coverage

Coverage policies from major commercial payers referencing D61.82.

12 policies

5 Medicare

Billing and Coding: Lab: Flow Cytometry
Policy ID: ART-55717
Billing and Coding: Flow Cytometry
Policy ID: ART-56464
Billing and Coding: Lab: Flow Cytometry
Policy ID: ART-57689
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing
Policy ID: ART-58710
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing
Policy ID: ART-58720

CPT Codes Commonly Billed with D61.82

Procedures frequently paired with this diagnosis based on PayerReady's Dx↔Px linkage data.

No procedure linkages on file for D61.82

We don't have CPT pairings indexed for this specific code yet. Use the CPT search above to find common procedures, or check your payer's published medical policy for code-specific guidance.

Convert D61.82 to ICD-9-CM

Per CMS General Equivalence Mappings (GEMs), useful for legacy data review and historical claim analysis.

ICD-10ICD-9Mapping Flags
D61.82 2842 00000

Flags format (5 digits): Approximate · No Map · Combination · Scenario · Choice List. Source: CMS 2017 GEMs (final version).

ICD-10 D61.82, Billing FAQ

Is ICD-10 code D61.82 billable? +

Yes, D61.82 is a billable ICD-10-CM code that can appear as a primary or secondary diagnosis on claims.

What other names or terms map to D61.82? +

ICD-10 D61.82 includes: Leukoerythroblastic anemia; Myelophthisic anemia; Panmyelophthisis.

What codes are Type 1 Excludes for D61.82? +

Type 1 Excludes (never code together with D61.82): idiopathic myelofibrosis (D47.1); myelofibrosis NOS (D75.81); myelofibrosis with myeloid metaplasia (D47.4)

Does D61.82 affect Medicare Advantage HCC risk adjustment? +

Yes. D61.82 maps to CMS-HCC v28 category 46. Capture this diagnosis annually for accurate Medicare Advantage risk score.

Is D61.82 a CC or MCC for inpatient DRG? +

Yes, this code is designated as CC. Documenting as a secondary diagnosis on inpatient claims can shift the DRG to a higher-weighted category.

What ICD-9 codes does D61.82 map to? +

Per CMS GEMs, D61.82 maps to ICD-9 codes: 2842. Useful for legacy data review and historical claim analysis.

Get the full PayerReady toolkit

Free access to CPT/ICD-10 lookup, denial appeals, fee comparator, and claim auditing with credentialing enrollment.

Start free →

Run this code through our claim audit tool

Check NCCI bundling, MUE limits, and modifier logic before submission.

Try the auditor →

Did this page help?

Quick signal so we know what to improve.

Thanks!

If you want a code reference page that doesn't exist yet, email coding@payerready.com.

Sorry to hear that.

Tell us what's missing or wrong: coding@payerready.com. We respond within 5 business days.

Reviewed by the PayerReady Medical Coding Team

Verified against the CMS 2026 code set on May 31, 2026.

Powered by 11K CPT · 98K ICD-10 · 860K MPFS rates · 4.5M NCCI edits · 9.5M NPIs. Our data methodology · About our coding team

Faster Approvals

Ready to Cut Your Enrollment Timeline in Half?

Join providers in all 50 states who handed off credentialing to a dedicated specialist. Create your free account in minutes and start enrolling the same day.

All 50 States Covered
No Long-Term Contracts
HIPAA HIPAA Compliant Platform
Dedicated Specialist Included